Across TCGA pan-cancer cohorts, IGHD6-13 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGHD6-13 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher IGHD6-13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHD6-13 expression acts as an unfavorable survival marker.

DLBC and UCEC are the cancer types where IGHD6-13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
UCEC	OS	Median	All	0.112	0.678	.009	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: IGHD6-13 tumor-vs-normal RNA expression · all IGHD6-13 data types